1. Localised
1.1. Low RIsk T1 -T2a + GS<7 + PSA <10
1.1.1. Observation
1.1.2. Radical Prostectomy
1.1.3. External Beam RT
1.1.4. Brachytherapy
1.2. Intermediate Risk T2b +GS =7 , PSA 10 -20
1.2.1. Radical Prostectomy
1.2.2. External Beam RT
1.2.3. Observation
1.2.4. Brachytheapy
1.3. High Risk T2C , GS 8-10, PSA>20
1.3.1. Radical Prostectomy
1.3.1.1. Recurrance
1.3.1.1.1. RT + ADT 6-24m
1.3.2. Neoadjuvant ADT 4m + EBRT + ADT 2y
1.3.2.1. Recurrance
1.3.2.1.1. High Intensity Focus US
1.3.2.1.2. HDR Brachytherapy
1.3.2.1.3. Radical Prostectomy
1.3.2.1.4. Observation
2. I I I I I I I I I
2.1. Recurrence
2.1.1. nmCRPC
2.1.1.1. Enzalutamide
2.1.1.2. Darolutamide
2.1.1.3. Apalutamide
2.1.2. nmCSPC
2.1.2.1. Only ADT
3. I I I I I I I I I I I I
3.1. PD
3.1.1. Docetaxel
3.1.1.1. Cabazitaxel
3.1.2. PRRT
3.1.3. Olaparib
3.1.4. Cabazitaxel
4. ADT
4.1. Orchidectomy
4.2. GnRH agonist
4.2.1. Goserilin - Zoledex
4.2.2. Leuprolin- Eligard /Lucrin
4.3. GnRH antagonist
4.3.1. Degarelix -Frimagon
4.3.2. Relugolix
5. Metastatic
5.1. mCSPC
5.1.1. ADT+ Novel antindrogen + Docetaxel
5.1.2. ADT+ Novel antiandrogen
5.1.2.1. Enzalutamide
5.1.2.2. Yonsa
5.1.2.3. Apalutamide
5.1.2.4. Darolutamide
5.1.3. ADT
5.1.4. Denosumab
5.2. mCRPC
5.2.1. ADT+ Novel antindrogen + Docetaxel
5.2.2. ADT+ Novel antiandrogen
5.2.2.1. Enzalutamide
5.2.2.2. Abiraterone
5.2.2.3. Yonsa
5.2.3. Denosumab